Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Aleniglipron

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Gasherbrum Bio, Inc · Phase 1 · Status n/r · Enrollment 70

NCT06139055

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tabletn/rn/rn/rn/r
Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsulen/rn/rn/rn/r
Part 2 (Cohort 1): GSBR-1290/Placebo Tabletn/rn/rn/rn/r
Part 2 (Cohort 2): GSBR-1290/Placebo Tabletn/rn/rn/rn/r
Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsulen/rn/rn/rn/r

Not shown

  • Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet: endpoint not reported
  • Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule: endpoint not reported
  • Part 2 (Cohort 1): GSBR-1290/Placebo Tablet: endpoint not reported
  • Part 2 (Cohort 2): GSBR-1290/Placebo Tablet: endpoint not reported
  • Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule: endpoint not reported